Quick Answer
Autolus Therapeutics plc reported Stockholders Equity of $178.13 million for fiscal year 2025.
Autolus Therapeutics plc Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $178.13M | -58.3% |
| 2024 | $427.32M | +283.3% |
| 2023 | $111.47M | -38.2% |
| 2023 | $180.52M | -21.3% |
| 2023 | $229.34M | -14.1% |
| 2023 | $266.92M | -10.6% |
| 2022 | $298.67M | +85.3% |
| 2022 | $161.15M | -24.9% |
| 2022 | $214.52M | -20.9% |
| 2022 | $271.14M | -13.5% |
| 2021 | $313.32M | +49.2% |
| 2020 | $210.03M | -17.6% |
| 2019 | $254.84M | +9.5% |
| 2018 | $232.64M | -8.9% |
| 2018 | $255.47M | +85.8% |
| 2017 | $137.51M | -3.6% |
| 2017 | $142.60M | +364.7% |
| 2016 | $30.69M | +192.2% |
| 2015 | $10.50M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $265.45M | -44.3% | -23.4% |
| June 30, 2025 | $346.46M | -34.4% | -6.6% |
| March 31, 2025 | $371.11M | -36.2% | -13.2% |
| December 31, 2024 | $427.32M | +283.3% | -10.4% |
| September 30, 2024 | $476.96M | +164.2% | -9.6% |
| June 30, 2024 | $527.84M | +130.2% | -9.3% |
| March 31, 2024 | $582.03M | +118.1% | +422.1% |
| December 31, 2023 | $111.47M | -62.7% | -38.2% |
- Autolus Therapeutics plc showed a decrease of -58.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2015–2025 period, Autolus Therapeutics plc’s stockholders equity has grown by 1596.3% (from $10.50 million to $178.13 million).
- The most recent figure is from Autolus Therapeutics plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: